The European Union accused the company of failing to comply with its contract to deliver the dose of the anti-Covid-19 vaccine.
The European Commission announced on Monday that it has taken legal action against AstraZeneca, accusing AstraZeneca of failing to fulfill its contract for delivery of the Covid-19 vaccine dose.
The European executive also believes that Anglo-Swiss Pharmaceuticals does not have sufficiently reliable plans to guarantee on-time delivery.
A spokesperson for the European Commission announced at a press conference on Monday: “The Commission took legal action against AstraZeneca last Friday.” He added that all 27 countries support this initiative.
Certain terms of the contract were not complied with
In response to this announcement, Anglo-Swiss Laboratories expressed regret and made it clear in the press release that it will fully defend itself in court because it stated that it has fully complied with the agreement reached with the European Commission.
A spokesperson for the European Commission said on Monday: “Certain terms of the contract were not complied with and the company failed to find a reliable strategy to ensure that the doses were delivered on time.”
ud83d udd34 flash memory-EU took legal action against AstraZeneca due to delays. The Swedish-British laboratory has been criticized for failing to comply with delivery promises. https://t.co/K0vQ5vZbPN pic.twitter.com/nbZTcysZFu
-Le Figaro (@Le_Figaro) April 26, 2021
He added: “We want to ensure that the dose is delivered quickly and adequately, because European citizens have the right to expect and follow the promises in the contract.”
AstraZeneca is committed to “doing its best”
According to the terms of the contract, AstraZeneca has pledged to “do its best” during the second quarter of 2021, to provide 180 million doses of the vaccine, which is now called Vaxzevria, which will be developed together with Oxford University, to the European Union during the second quarter of 2021.
It is expected that the total delivery volume will reach 300 million doses throughout the first half of the year.
However, the pharmaceutical group announced in a statement issued in mid-March that due to production problems and export restrictions, the drug can only provide 100 million doses. The following week, European executives sent him an official notice to try to resolve the dispute.
AstraZeneca announced on Monday that, according to forecasts, it will provide nearly 50 million doses to European countries by the end of the month.
The pharmaceutical group stated that it has made progress in solving the technical problems it faces, which translates into an increase in production.